HealthCare Global Enterprises Gelecekteki Büyüme

Future kriter kontrolleri 4/6

HealthCare Global Enterprises kazanç ve gelirin sırasıyla yıllık 42.8% ve 13.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 45.9% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

42.8%

Kazanç büyüme oranı

45.9%

EPS büyüme oranı

Healthcare kazanç büyümesi	26.9%
Gelir büyüme oranı	13.3%
Gelecekteki özkaynak getirisi	12.5%
Analist kapsamı	Good
Son güncelleme	08 Oct 2024

Gelecekteki son büyüme güncellemeleri

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11

Recent updates

We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

Sep 19

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Feb 11

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

Sep 14

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

Sep 05

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

May 17

Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Jun 24

Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Jun 03

Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

Dec 08

What Does HealthCare Global Enterprises Limited's (NSE:HCG) Share Price Indicate?

Jun 25

Insider Buying: The HealthCare Global Enterprises Limited (NSE:HCG) Executive Chairman Just Bought ₹2.4m Worth Of Shares

Mar 14

The HealthCare Global Enterprises (NSE:HCG) Share Price Is Up 51% And Shareholders Are Holding On

Mar 03

Here's Why HealthCare Global Enterprises (NSE:HCG) Can Afford Some Debt

Jan 27

How Many HealthCare Global Enterprises Limited (NSE:HCG) Shares Did Insiders Buy, In The Last Year?

Dec 23

Kazanç ve Gelir Büyüme Tahminleri

NSEI:HCG - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	29,189	2,206	N/A	N/A	2
3/31/2026	25,097	1,207	1,557	N/A	9
3/31/2025	22,291	745	-294	N/A	8
6/30/2024	19,770	526	N/A	N/A	N/A
3/31/2024	19,121	482	989	2,846	N/A
12/31/2023	18,592	353	N/A	N/A	N/A
9/30/2023	18,140	371	922	2,197	N/A
6/30/2023	17,471	309	N/A	N/A	N/A
3/31/2023	16,944	293	1,184	2,516	N/A
12/31/2022	16,174	270	N/A	N/A	N/A
9/30/2022	15,507	-264	1,156	2,364	N/A
6/30/2022	14,827	694	N/A	N/A	N/A
3/31/2022	13,978	537	1,489	2,201	N/A
12/31/2021	13,312	-544	N/A	N/A	N/A
9/30/2021	12,472	-379	1,089	1,510	N/A
6/30/2021	11,431	-1,633	N/A	N/A	N/A
3/31/2021	10,134	-1,935	851	1,205	N/A
12/31/2020	9,858	-1,349	N/A	N/A	N/A
9/30/2020	9,897	-1,284	751	1,271	N/A
6/30/2020	10,202	-1,284	N/A	N/A	N/A
3/31/2020	10,956	-1,067	223	1,301	N/A
12/31/2019	10,832	-718	N/A	N/A	N/A
9/30/2019	10,541	-552	N/A	N/A	N/A
6/30/2019	10,210	-394	N/A	N/A	N/A
3/31/2019	9,787	-248	-903	985	N/A
12/31/2018	9,430	-135	N/A	N/A	N/A
9/30/2018	9,004	-41	N/A	N/A	N/A
6/30/2018	8,661	124	N/A	N/A	N/A
3/31/2018	8,307	205	N/A	978	N/A
12/31/2017	7,909	257	N/A	N/A	N/A
9/30/2017	7,608	278	N/A	N/A	N/A
6/30/2017	7,237	219	N/A	N/A	N/A
3/31/2017	7,001	230	N/A	913	N/A
12/31/2016	6,705	208	N/A	N/A	N/A
9/30/2016	6,392	133	N/A	N/A	N/A
6/30/2016	6,081	67	N/A	N/A	N/A
3/31/2016	5,842	-178	N/A	732	N/A
12/31/2015	5,611	-33	N/A	N/A	N/A
9/30/2015	5,494	9	N/A	763	N/A
6/30/2015	5,323	9	N/A	N/A	N/A
3/31/2015	5,194	8	N/A	597	N/A
3/31/2014	4,513	-356	N/A	514	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: HCG 'nin tahmini kazanç büyümesi (yıllık 42.8% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: HCG şirketinin kazançlarının (yıllık 42.8% ) Indian pazarından (yıllık 17.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: HCG şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: HCG şirketinin gelirinin (yıllık 13.3% ) Indian pazarından (yıllık 10.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: HCG şirketinin gelirinin (yıllık 13.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: HCG 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.5 %).

HealthCare Global Enterprises Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 16%, revenue upgraded

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 16%

Consensus EPS estimates increase by 12%

Consensus EPS estimates fall by 11%

Price target decreased to ₹350

Recent updates

HealthCare Global Enterprises Limited to Report Q2, 2025 Results on Nov 09, 2024

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of 51% stake in Vizag Hospital and Cancer Research Centre Private Limited.

We Take A Look At Why HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation Is Well Earned

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 25, 2024

Consensus EPS estimates fall by 16%, revenue upgraded

First quarter 2025 earnings released: EPS: ₹0.87 (vs ₹0.55 in 1Q 2024)

HealthCare Global Enterprises Limited to Report Q1, 2025 Results on Aug 08, 2024

HealthCare Global Enterprises Limited (NSEI:HCG) entered into share purchase agreement to acquire 51% stake in Vizag Hospital and Cancer Research Centre Private Limited for INR 2.1 billion.

HealthCare Global Enterprises Limited to Report Q4, 2024 Results on May 29, 2024

Temasek May Bid for CVC's 60% Stake in Healthcare Global

EQT, TPG and KKR Reportedly Eye Majority Stake in HCG

New major risk - Financial position

HealthCare Global Enterprises Limited Just Missed EPS By 79%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

HealthCare Global Enterprises Limited to Report Q3, 2024 Results on Feb 08, 2024

Consensus EPS estimates fall by 16%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

HealthCare Global Enterprises Limited to Report Q2, 2024 Results on Nov 09, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Radiation Business from Amrish Oncology Services Private Limited.

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Oncology Business from SRJ Health Care Private Limited.

CVC Capital Mulls Selling Stake in HealthCare Global Enterprises

We Think Shareholders Will Probably Be Generous With HealthCare Global Enterprises Limited's (NSE:HCG) CEO Compensation

A Look At The Fair Value Of HealthCare Global Enterprises Limited (NSE:HCG)

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 20, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) completed the acquisition of Nagpur Cancer Hospital & Research Institute Private Limited from Ajay Mehta, Suchitra Mehta and other shareholders.

HealthCare Global Enterprises Limited Announces CFO Changes

Consensus EPS estimates increase by 12%

New major risk - Financial position

HealthCare Global Enterprises Limited (NSEI:HCG) executed business transfer agreement to acquire Radiation Business from Amrish Oncology Services Private Limited for INR 160 million.

First quarter 2024 earnings: EPS misses analyst expectations

HealthCare Global Enterprises Limited to Report Q1, 2024 Results on Aug 10, 2023

HealthCare Global Enterprises Limited (NSEI:HCG) entered into a share purchase agreement to acquire Nagpur Cancer Hospital & Research Institute Private Limited from Ajay Mehta, Suchitra Mehta and other shareholders for approximately INR 140 million.

Executive Chairman recently sold ₹1.1b worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 11%

HealthCare Global Enterprises Limited's (NSE:HCG) Business Is Yet to Catch Up With Its Share Price

HealthCare Global Enterprises Limited to Report Q4, 2023 Results on May 25, 2023

Insider recently sold ₹794k worth of stock

Insider recently sold ₹1.7m worth of stock

Insider recently sold ₹2.9m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

HealthCare Global Enterprises Limited to Report Q3, 2023 Results on Feb 09, 2023

Insider recently sold ₹846k worth of stock

Insider recently sold ₹332k worth of stock

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹0.53 (vs ₹8.22 in 2Q 2022)

HealthCare Global Enterprises Limited to Report Q2, 2023 Results on Nov 10, 2022

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 29, 2022

HealthCare Global Enterprises Limited, Annual General Meeting, Sep 29, 2022

Price target decreased to ₹350

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

HealthCare Global Enterprises Limited to Report Q1, 2023 Results on Aug 10, 2022

Executive Chairman recently sold ₹500m worth of stock

HealthCare Global Enterprises Limited (BSE:539787) agreed to acquire Radiation therapy centre of Radiant Hospital Services Private Limited from Radiant Hospitality Services Private Limited for INR 160 million.

Does HealthCare Global Enterprises (NSE:HCG) Have A Healthy Balance Sheet?

Now 21% undervalued

Shareholders Shouldn’t Be Too Comfortable With HealthCare Global Enterprises' (NSE:HCG) Strong Earnings

Price target increased to ₹377

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to ₹293

HealthCare Global Enterprises Limited to Report Fiscal Year 2022 Results on May 26, 2022

High number of new and inexperienced directors

Insider recently sold ₹719k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Healthcare Global Enterprises Limited Announces Board Appointments

Is HealthCare Global Enterprises (NSE:HCG) Using Too Much Debt?

Non-Executive Independent Director Shanker Annaswamy has left the company

Price target increased to ₹266

Second quarter 2022 earnings released: EPS ₹8.22 (vs ₹1.94 loss in 2Q 2021)